VCYT Veracyte Inc

Price (delayed)

$23.58

Market cap

$1.8B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.93

Enterprise value

$1.61B

Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other ...

Highlights
Veracyte's gross profit has increased by 24% YoY and by 3.7% QoQ
Veracyte's revenue has increased by 21% YoY and by 4% QoQ
The EPS has dropped by 127% year-on-year but it has increased by 9% since the previous quarter
Veracyte's net income has shrunk by 126% YoY but it has increased by 8% QoQ
The debt has grown by 11% from the previous quarter

Key stats

What are the main financial stats of VCYT
Market
Shares outstanding
76.45M
Market cap
$1.8B
Enterprise value
$1.61B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.58
Price to sales (P/S)
4.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.28
Earnings
Revenue
$375.47M
EBIT
-$70.43M
EBITDA
-$39.93M
Free cash flow
$26.33M
Per share
EPS
-$0.93
Free cash flow per share
$0.35
Book value per share
$14.9
Revenue per share
$5.02
TBVPS
$4.41
Balance sheet
Total assets
$1.2B
Total liabilities
$81.42M
Debt
$14.04M
Equity
$1.12B
Working capital
$232.37M
Liquidity
Debt to equity
0.01
Current ratio
5
Quick ratio
4.43
Net debt/EBITDA
4.91
Margins
EBITDA margin
-10.6%
Gross margin
68.5%
Net margin
-18.2%
Operating margin
-21.3%
Efficiency
Return on assets
-5.9%
Return on equity
-6.3%
Return on invested capital
-109.9%
Return on capital employed
-6.2%
Return on sales
-18.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VCYT stock price

How has the Veracyte stock price performed over time
Intraday
0.68%
1 week
-1.46%
1 month
3.74%
1 year
-17.35%
YTD
-14.29%
QTD
8.81%

Financial performance

How have Veracyte's revenue and profit performed over time
Revenue
$375.47M
Gross profit
$257.34M
Operating income
-$79.95M
Net income
-$68.18M
Gross margin
68.5%
Net margin
-18.2%
Veracyte's net income has shrunk by 126% YoY but it has increased by 8% QoQ
The operating income has plunged by 120% YoY but it has grown by 7% from the previous quarter
The net margin has plunged by 88% YoY but it has grown by 12% from the previous quarter
The operating margin has plunged by 82% YoY but it has grown by 11% from the previous quarter

Growth

What is Veracyte's growth rate over time

Valuation

What is Veracyte stock price valuation
P/E
N/A
P/B
1.58
P/S
4.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.28
The EPS has dropped by 127% year-on-year but it has increased by 9% since the previous quarter
The P/B is 49% below the 5-year quarterly average of 3.1 and 8% below the last 4 quarters average of 1.7
The equity has grown by 7% from the previous quarter and by 3.5% YoY
The P/S is 56% below the 5-year quarterly average of 10.7 and 9% below the last 4 quarters average of 5.1
Veracyte's revenue has increased by 21% YoY and by 4% QoQ

Efficiency

How efficient is Veracyte business performance
VCYT's return on invested capital has dropped by 159% year-on-year but it is up by 11% since the previous quarter
The ROA has plunged by 127% YoY but it has grown by 9% from the previous quarter
The company's return on equity has shrunk by 125% YoY but it rose by 10% QoQ
The return on sales has dropped by 94% year-on-year but it has increased by 11% since the previous quarter

Dividends

What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VCYT.

Financial health

How did Veracyte financials performed over time
The total liabilities has grown by 15% from the previous quarter and by 7% YoY
The company's current ratio rose by 11% YoY and by 7% QoQ
The debt is 99% less than the equity
The debt has grown by 11% from the previous quarter
The equity has grown by 7% from the previous quarter and by 3.5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.